Search research articles
Contact Us
Filters
Showing results (41-50 of 306) with videos related to
Page
of 31
Sort By:
Epilepsia
|
July 6, 2020
Response: Cannabidiol antiseizure activity and its interactions with clobazam: "It's déjà vu all over again" Yogi Berra
Meir Bialer, Emilio Perucca
Epilepsia
|
May 27, 2020
Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials
Meir Bialer, Emilio Perucca
Current Opinion in Neurology
|
February 2, 2026
Novel pharmacological therapies in development
Piero Perucca, Emilio Perucca
Expert Opinion on Drug Metabolism & Toxicology
|
June 4, 2015
CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects
Valentina Franco, Emilio Perucca
Expert Review of Neurotherapeutics
|
October 9, 2009
Challenges in the pharmacotherapy of the epilepsies
Giuliana Gatti, Emilio Perucca
Drugs
|
March 1, 2026
Antiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades
Meir Bialer, Emilio Perucca
CNS Drugs
|
June 7, 2020
Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications
Emilio Perucca, Meir Bialer
BMJ (Clinical Research Ed.)
|
November 20, 2004
Revisiting phenobarbital for epilepsy
Rajendra Kale, Emilio Perucca
Current Opinion in Neurology
|
November 16, 2004
Epilepsy after head injury
Raimondo D'Ambrosio, Emilio Perucca
Expert Review of Neurotherapeutics
|
September 2, 2015
The pharmacogenomics of epilepsy
Valentina Franco, Emilio Perucca
Page
of 31
Search research articles
Search
Showing results (41-50 of 306) with videos related to
Sort By:
Page
of 31
Epilepsia
|
July 6, 2020
Response: Cannabidiol antiseizure activity and its interactions with clobazam: "It's déjà vu all over again" Yogi Berra
Meir Bialer, Emilio Perucca
Epilepsia
|
May 27, 2020
Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials
Meir Bialer, Emilio Perucca
Current Opinion in Neurology
|
February 2, 2026
Novel pharmacological therapies in development
Piero Perucca, Emilio Perucca
Expert Opinion on Drug Metabolism & Toxicology
|
June 4, 2015
CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects
Valentina Franco, Emilio Perucca
Expert Review of Neurotherapeutics
|
October 9, 2009
Challenges in the pharmacotherapy of the epilepsies
Giuliana Gatti, Emilio Perucca
Drugs
|
March 1, 2026
Antiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades
Meir Bialer, Emilio Perucca
CNS Drugs
|
June 7, 2020
Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications
Emilio Perucca, Meir Bialer
BMJ (Clinical Research Ed.)
|
November 20, 2004
Revisiting phenobarbital for epilepsy
Rajendra Kale, Emilio Perucca
Current Opinion in Neurology
|
November 16, 2004
Epilepsy after head injury
Raimondo D'Ambrosio, Emilio Perucca
Expert Review of Neurotherapeutics
|
September 2, 2015
The pharmacogenomics of epilepsy
Valentina Franco, Emilio Perucca
Page
of 31